Ngaio Diagnostics reached out to Biomedica due to a request from one of their customers. After speaking to some of his key customers it was clear for Stuart McKenzie, Managing Director of Ngaio Diagnostics, that “Biomedica’s unique kit range and great reputation for excellent kits” were a perfect fit to Ngaio’s current distribution portfolio.
For Biomedica “Ngaio is the right partner and well placed to market Biomedica’s biomarker ELISAs to the research & clinical market on the other side of the world.”
Ngaio Diagnostics is a privately owned laboratory supply company based in Nelson, New Zealand. Established in 1991, we specialise in the distribution and support of quality products to hospital laboratories, community clinical laboratories, veterinary laboratories, veterinary practices, food testing & environmental laboratories and food processors. https://bit.ly/2SzEST2
Serum levels of sclerostin reflect altered bone microarchitecture in patients with hepatic cirrhosis. Sclerostin, a glycoprotein secreted mainly by osteocytes, regulates bone mass by decreasing bone formation.
In patients with hepatic cirrhosis, areal bone mineral density (aBMD) is decreased especially at the lumbar spine. aBMD alone can be insufficient to explain increased fracture risk and bone microarchitecture can provide additional information. However, since assessment of bone microarchitecture is complex, biomarkers could help assess fracture risk. In a study of several biomarkers, Wakolbinger et al. found a correlation between sclerostin and altered bone microarchitecture in hepatic cirrhosis https://link.springer.com/article/10.1007/s00508-019-01595-8.
Biomedica´s bioactive sclerostin ELISA measures bioactive sclerostin by using a monoclonal antibody directed at the LRP5/6 binding region, capturing all circulating sclerostin forms containing the free-receptor binding site. It is validated in depth according to FDA quality standards, to ensure the ELISA reliability.
WorldHeartDay is celebrated to draw attention to heart illness and the range of associated health issues. The day aims to promote different preventative steps and changes in lifestyle to avoid any cardiovascular diseases, like heart attack, stroke, heart failure and any other condition related to the same.
On average, more than 17 million people die from heart-related illnesses every year.
Biomedica offers a range of biomarker assays for the early detection of heart disease https://lnkd.in/euWE-gc including tests for the detection of natriuretic peptides, which have proven to be powerful diagnostic and prognostic biomarkers of heart disease https://lnkd.in/eGnun-N.
Did you know that levels of NT-proANP might affect metabolic syndrome (MetS) differently in men and women?
Atrial natriuretic peptide (ANP) plays a key role in human metabolism and cardiometabolic disorders. Metabolic syndrome (MetS), a combination of obesity with other disease states of homeostasis of fats, sugars and proteins in the body, increases the risk of developing cardiovascular diseases and diabetes. In a study by Guo et al. NT-proANP had a protective effect against MetS in men. Men with high levels of NT-proANP had 0.60 times the risk of having MetS compared with men with low levels of NT-proANP. By contrast, women in the upper NT-proANP quartile group had 1.10 times the risk of having MetS compared to the lower quartile group. This suggests that NT-proANP may affect MetS differently in men and women.
Learn more at: Gender difference of association between plasma N-terminal pro-atrial natriuretic peptide and metabolic syndrome https://bit.ly/2RsHeCy
And check out the Biomedica NT-proANP ELISA:
• CE marked – for IVD use in the EU
• Small sample volume – 10 µl / well
• Assay suitable for rat/mouse samples – NT-proANP as a cardiovascular safety biomarker in rats
Leucine-rich alpha-2-glycoprotein (LRG/LRG1) is an innovative biomarker for inflammation and angiogenesis.
Recently, researchers investigated for the first time the association between plasma LRG with cardiovascular comorbidities in hemodialysis patients with end stage renal disease:
LRG can reliably be measured by ELISA in human serum, plasma and urine samples with a fully validated assay. Only 5 µl of sample volume is required!
• SPECIFIC – Characterized, epitope mapped antibodies
• CONVENIENT – Assay range optimized for clinical samples
• RELIABLE – Rigorously validated according to FDA/EMEA/ICH guidelines
• EASY -Results in 3 h, all reagents included
Find out more: human LRG ELISA
Researchers have identified the soluble WNT pathway inhibitor SCLEROSTIN as an independent risk factor for all-cause #mortality in patients after kidney transplantation.
600 stable renal transplant recipients were followed for all-cause mortality for 3 years.
Sclerostin is an independent risk factor for all-cause mortality in kidney transplant recipients.
Zeng S et al., Clin Exp Nephrology (2020). Click link for full text.
Biomedica Sclerostin ELISA: https://www.bmgrp.com/product/cardiovascular/sclerostin-elisa-human-sost-biomedica/
√ HIGH QUALITY – fully validated assay according to ICH/FDA/EMEA guidelines
√ LOW SAMPLE VOLUME – only 20 µl sample / well
√ EASY – convenient ready to use protocol
√ MOST REFERENCED Sclerostin ELISA
Also available: Bioactive Sclerostin ELISA https://www.bmgrp.com/product/cardiovascular/biomedica-bioactive-sclerostin-elisa-human-sost/
√ specific antibodies targeting the receptor binging region
Leucine-rich alpha-2-glycoprotein 1 (LRG1) is a new oncogene-related gene, which has been proven important for the development and poor prognosis of human cancers.
Researchers recently explored the prognostic impact of LRG in postoperative intrahepatic cholangiocarcinoma (ICC) and assessed the association between tumor LRG and factors such as TGF-β1, IL-6, and the tumor microvessel density.
LRG can reliably be measured by ELISA in human serum, plasma and urine samples with a fully validated assay. Only 5 µl of sample volume is required!
• SPECIFIC – Characterized, epitope mapped antibodies
• CONVENIENT – Assay range optimized for clinical samples
• RELIABLE – Rigorously validated according to FDA/EMEA/ICH guidelines
• EASY -Results in 3 h, all reagents included
Find out more: human LRG ELISA
Delirium is a common and major complication subsequent to cardiac surgery. Despite scientific efforts, there are no parameters which reliably predict postoperative delirium. In delirium pathology, natriuretic peptides (NPs) interfere with the blood–brain barrier and thus promote delirium. A recent study by Saller et al. , which used the Biomedica NT-proCNP ELISA, found a positive correlation between delirium and preoperative plasma levels of ANP and serum levels NT-proCNP. Both ANP and NT-proCNP predicted delirium, but did not correlate with postoperative survival or long-term cognitive decline.
Natriuretic Peptides as a Prognostic Marker for Delirium in Cardiac Surgery-A Pilot Study.
Saller T, et al. Medicina. 2020;56(6):258.
Check out the Biomedica the NT-proCNP ELISA
• CE marked
• Protocols for urine, cell culture and non-human samples
And the NT-proANP ELISA
• CE marked
• Small sample volume – 10 µl / well
• Assay suitable for rat/mouse samples
Major depressive disorder and bipolar disorder are accompanied by higher loads of Gram-negative bacteria. This is associated with the invasion of gut bacteria into extraintestinal sites, such as the mesenteric lymph node complex, liver, spleen, kidney, and bloodstream (leaky gut). In response, oxidative stress pathways and #autoimmune responses to oxidative specific epitopes are activated in mood disorders.
If replicated, drugs that protect the integrity of the gut barrier may offer novel therapeutic opportunities for bipolar disorder and major depressive disorder.
Simeonova D, Stoyanov D, Leunis JC, et al. Increased Serum Immunoglobulin Responses to Gut Commensal Gram-Negative Bacteria in Unipolar Major Depression and Bipolar Disorder Type 1, Especially When Melancholia Is Present. Neurotox Res. 2020;37(2):338-348.
Oxidative stress was measured with the Biomedica oxidized LDL (oxLDL) ELISA
• High specificity to MDA adducts
• Small sample volume – 20 µl / well
• Direct measurement
Also check out our oLAB (Anti-Oxidized LDL Autoantibodies) ELISA
• CE marked – for IVD use in the EU
• Only 2 h 15 min total incubation time
• 2 controls included
We offer custom analytical testing services for all our own and other manufacturers’ ELISAs, Luminex assays, microRNA analysis, and glycan profiling.
Advantages of Using Biomedica Biomarker Testing Services
• Quality: High-quality products chosen to ensure reliable data
• Expertise: Experienced staff with hands-on know how in research and IVD-test development
• Flexibility: Customized according to your project needs and budget
• Speed: Rapid turn-around times to meet your deadlines
• Results: Comprehensive results presented in an analytical report
Learn more at https://www.bmgrp.com/service-measurement-biomedica/
When using an ELISA kit, you want to ensure that results are specific, accurate, sensitive, and reproducible,
ELISA assay reliability is important and having access to the assay´s validation data before making a purchase decision is an advantage. Not every ELISA kit supplier offers the same level of assay validation.
This is one of the reasons why the ELISA kits on the market vary so much and one should choose them with care.
In a fully validated ELISA, all components are rigorously tested and therefore fit perfectly together. This minimizes the sources of error, increasing specificity, accuracy, and reproducibility.
ELISA Assay Reliability
At Biomedica we develop and manufacture our ELISA assays with care
All Biomedica kits are fully validated and come with sample data for healthy human subjects, ready-to-use standards and controls. To increase transparency, we publish our validation data on our website. To learn more, check out https://www.bmgrp.com/quality .
Related literature
Practical Guide to Immunoassay Method Validation. Andreasson U, Perret-Liaudet A, van Waalwijk van Doorn LJ, Blennow K, Chiasserini D, Engelborghs S, Fladby T, Genc S, Kruse N, Kuiperij HB, Kulic L, Lewczuk P, Mollenhauer B, Mroczko B, Parnetti L, Vanmechelen E, Verbeek MM, Winblad B, Zetterberg H, Koel-Simmelink M, Teunissen CE. AFront Neurol. 2015 Aug 19;6:179. doi: 10.3389/fneur.2015.00179. PMID: 26347708; PMCID: PMC4541289.
Abstract
Biochemical markers have a central position in the diagnosis and management of patients in clinical medicine, and also in clinical research and drug development, also for brain disorders, such as Alzheimer’s disease. The enzyme-linked immunosorbent assay (ELISA) is frequently used for measurement of low-abundance biomarkers. However, the quality of ELISA methods varies, which may introduce both systematic and random errors. This urges the need for more rigorous control of assay performance, regardless of its use in a research setting, in clinical routine, or drug development. The aim of a method validation is to present objective evidence that a method fulfills the requirements for its intended use. Although much has been published on which parameters to investigate in a method validation, less is available on a detailed level on how to perform the corresponding experiments. To remedy this, standard operating procedures (SOPs) with step-by-step instructions for a number of different validation parameters is included in the present work together with a validation report template, which allow for a well-ordered presentation of the results. Even though the SOPs were developed with the intended use for immunochemical methods and to be used for multicenter evaluations, most of them are generic and can be used for other technologies as well.
The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) Concentrations.Recent advancements in genetic #research have uncovered new forms of monogenic #osteoporosis. Mutations in WNT1, encoding a WNT/β-catenin pathway ligand WNT1, and PLS3, encoding X chromosomally inherited plastin 3 (PLS3), both result in early-onset osteoporosis with prevalent fractures and disrupted bone metabolism.
Data from a study by Mäkitie RE et al. indicate a link between PLS3 and DKK1 and WNT1 and FGF23 in bone metabolism (measured with biomedica kits). Therefore, DKK1 and FGF23 may be clinically useful biomarkers for PLS3 and WNT1 osteoporosis, respectively.
Check out the Biomedica DKK-1 and FGF23 ELISA kits:
– Reliable – validated according to international guidelines
– Specific – epitope mapped antibodies
– CE marked – widely cited in clinical studies
Biomarkers in WNT1 and PLS3 Osteoporosis: Altered Concentrations of DKK1 and FGF23 . Mäkitie RE et al., J Bone Miner Res, 2020 May;35(5):901-912.
Endothelin-1 (ET-1) is a potent vasoconstrictor secreted by vascular endothelial cells. Due to its high biologic activity, ET-1 is rapidly cleared. However, big ET-1, the precursor of ET-1, has a much longer half-life, circulates in higher concentrations and is easier to detect. Thus, big-ET-1 is a more suitable marker and can be used as an alternative approach for the indirect estimation of ET-1 release. Big ET-1 has been implicated in the pathophysiology of numerous cardiovascular diseases.
Did you know?
Big ET can easily be measured using Biomedica’s Big ET ELISA:
√ Direct measurement – highly sensitive
√ CE marked – for IVD use in EU
√ Fully validated according to FDA/ICH/EMEA guidelines
√ Published cut-off values for Three vessel disease (TVD)
Literature:
Prognostic Value of Plasma Big Endothelin-1 Level Among Patients with Three-Vessel Disease: A Cohort Study. https://doi.org/10.5551/jat.47324.
Association of Baseline Big Endothelin-1 Level With Long-Term Prognosis Among Cardiac Resynchronization Therapy Recipients. https://pubmed.ncbi.nlm.nih.gov/29913121/
The Association between Plasma Big Endothelin-1 Levels at Admission and Long-Term Outcomes in Patients with Atrial Fibrillation.https://doi.org/10.1016/j.atherosclerosis.2018.02.034.
The Value of Big Endothelin-1 in the Assessment of the Severity of Coronary Artery Calcification. https://doi.org/10.1177/1076029618764846.
Soluble RANKL is physiologically dispensable but accelerates tumour metastasis to bone.
Asano T. et al., Nat. Metab. 2019, 1: 868–875.
Data from a study by Asano et al. suggest that membrane-bound RANKL is sufficient for most physiological RANKL functions. By contrast, soluble RANKL specifically contributes to bone metastasis by exerting a chemotactic activity in tumour cells expressing RANK thus attracting them to the bone.
Therefore, measurement of the serum RANKL level may help to identify patients who have a high risk of developing bone metastasis and inhibiting soluble RANKL alone may lead to the development of a new therapeutic strategy.
RANKL can easily be measured in serum:
√ HIGH SENSITIVITY – measurable concentrations in healthy subjects
√ Only ELISA that measures free uncomplexed soluble RANKL
√ CE-marked – widely cited in clinical studies
Also available:
OPG ELISA – most referenced
Learn more: RANKL biology: bone metabolism, the immune system, and beyond.
Ono T. et al., Inflamm. Regen. 2020; 40: 2. Full text
Multiple Myeloma (MM) is a malignant proliferative disease of plasma cells in the bone marrow that remains largely untreatable. Patients develop osteolytic lesions, which frequently lead to skeletal-related events and pathological fractures.
Myeloma-induced bone destruction is based on increased bone resorption and decreased bone formation, which are induced by the interaction between myeloma cells and the bone marrow microenvironment. Myeloma cells induce RANKL expression in stromal cells and suppress OPG expression. In a murine model of MM, RANKL has been shown to induce myeloma cell release from dormancy through osteoclastic bone resorption, thereby promoting disease progression and/or relapse.
Administration of the therapeutic antagonist for RANKL in myeloma (RANK-Fc) decreased tumor burden and the production of MM -promoting cytokines. In line with these observations, bone resorption is related to tumor burden, and Denosumab, a RANKL inhibitor, has been shown to prevent skeletal-related events.
To learn more about RANKL’s role in multiple myeloma check out https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006158/ & https://pubmed.ncbi.nlm.nih.gov/30093448/.
Biomedica free soluble RANKL ELISA highlights :
- High sensitivity – measurable concentrations in healthy subjects
- Only ELISA that measures free, uncomplexed soluble RANKL
- CE marked
Check out the recently published graphical abstract for: Endostatin is an independent risk factor of graft loss after kidney transplant. Chu C et al., Am J Nephrol. 2020 Apr 22;51(5):373-380.
Biomedica’s FULLY VALIDATED human and mouse/rat Endostatin ELISAs
Human Endostatin can easily be measured by ELISA assay
√ for serum, plasma, and urine samples
√ SIMPLE analysis – results in 4.5 h
√ LOW SAMPLE VOLUME – only 20µl sample / well
√ HIGH QUALITY – fully validated assay according to ICH/FDA/EMEA
Also available:
Mouse/Rat Endostatin ELISA – only 5µl sample volume required
Researchers identified the soluble bone metabolism biomarker DKK-1 to be independently associated with future cardiovascular events, which are primarily driven by increased risk of stroke.
Associations of Serum Dickkopf‐1 and Sclerostin With Cardiovascular Events: Results From the Prospective Bruneck Study.
Klingenschmid G et al., JAHA 2020; Mar 17;9(6):e014816.
Serum DKK-1 can easily be measured by ELISA assay
√ SIMPLE analysis – direct measurement – results in 3.5 h
√ LOW SAMPLE VOLUME – only 20µl sample / well
√ HIGH QUALITY Assay – fully validated
√ WIDELY USED – >100 citations
√ CE marked – for IVD use in EU!
Interested in performing a study? Contact us for your special offer :
e-mail, or phone: +43-1-29107-45.
We are confident that Scandinavian customers will benefit from BioNordika’s long history and experiences as well as local offices to directly service their needs as they are used to receive from Biomedica.
The BIONORDIKA GROUP was founded during 1986-1989 and currently employs around 50 people in the five offices in Sweden, Denmark, Norway, Estonia and Finland with the idea of being an “interface of science” between advance niche life science product/services suppliers and customers in Scandinavia/Nordics via a streamlined platform.
For details and contact information please visit:
BioNordica AB, Sweden (also for Estonia)
The expression level of klotho decreases in patients with #CKD (chronic kidney disease) and is accompanied by renal disorders.
In rodent models with CKD, #KLOTHO deficiency causes high circulating levels of phosphate and vascular calcification. Conversely, overexpression of klotho can enhance phosphaturia, improve renal function, and reduce calcification.
In CKD, KLOTHO levels start declining due to altered activin and ActRIIA signalling. This in turn limits KLOTHO’s regulation of FGF23 production and leaves #hyperphosphataemia as the principal regulator of FGF23 secretion in CKD.
Since KLOTHO levels change at an early stage of CKD, KLOTHO is a sensitive biomarker for the decline in kidney function.
To learn more about the mechanism of KLOTHO signalling check out https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-018-1094-z.
Learn more about our KLOTHO assay
- CE-certified
- convenient (direct measurement, 10µl sample/well only)
- highly specific
- highly sensitive
- fully validated
Researchers from Germany have identified the endothelial basement membrane biomarker endostatin that can better predict the risk of graft loss in kidney transplant recipients (KTRs) in a prospective observational cohort study with 574 maintenance KTRs (median follow-up 48 months).
“.. increased serum endostatin concentrations at baseline are independently associated with the risk of graft loss in prevalent KTRs. Its association with graft loss seems to be even stronger as compared to the established classical risk factors for graft loss: decreased GFR and increased urinary protein excretion.“
Endostatin is an independent risk factor of graft loss after kidney transplant. Chu C et al., Am J Nephrol. 2020 Apr 22;51(5):373-380.
Biomedica’s FULLY VALIDATED human and mouse/rat Endostatin ELISAs
Human Endostatin can easily be measured by ELISA assay
√ for serum, plasma, and urine samples
√ SIMPLE analysis – results in 4.5 h
√ LOW SAMPLE VOLUME – only 20µl sample / well
√ HIGH QUALITY – fully validated assay according to ICH/FDA/EMEA
Also available:
Mouse/Rat Endostatin ELISA – only 5µl sample volume required
Why is it important to measure the ratio of active intact and inactive C-terminal FGF23 fragments?
FGF23 is an endocrine hormone regulating phosphate homeostasis by modulating renal phosphate reabsorption, vitamin D metabolism and parathyroid hormone (PTH) secretion. Epidemiological data suggests that higher FGF23 concentrations are associated with all-cause mortality, cardiovascular mortality, a higher risk of myocardial infarction, stroke and heart failure.
Levels of FGF23 and intact: C-terminal fragment FGF23 ratios can be altered in both genetic and acquired diseases. A primary excess in circulating intact FGF23 is the underlying cause of diseases like XLH, ADHR/ARHR or tumor-induced osteomalacia. The excessive FGF23 levels in these diseases cause renal phosphate wasting, low active vitamin D concentrations and defective mineralization of bones. By contrast, during iron deficiency FGF23 synthesis and cleavage are upregulated in a coupled manner, resulting in normal levels of intact FGF23 and high levels of cFGF23.
Therefore, different conditions result in varying characteristic iFGF23:cFGF23 ratios.
For more information on why iFGF23:cFGF23 ratios differ between diseases check out “Coupling Fibroblast Growth Factor 23 Production and Cleavage: Iron Deficiency, Rickets, and Kidney Disease” or check out out iFGF23 and cFGF12 ELISA.
Meet us at the Osteologie 2020, hosted by the Deutsche Gesellschaft für Endokrinologie and the Österreichische Gesellschaft für Knochen- und Mineralstoffwechsel, taking place from 12-14 March 2020 in Salzburg, Austria!
We will exhibit together with our partners Fianostics & TAmiRNA at booth #1.
Moreover, we will present out new VEGF-A ELISA at our poster “Novel VEGF-A ELISA allows sensitive quantification of human total bioactive VEGF-A” on Thursday, 12th March between 5-5.30pm.
In addition, our TAmiRNA partner Dr. Matthias Hackl will give two talks “mikroRNAs als neue therapeutische Targets für muskuloskelettale
Erkrankungen” and “MicroRNA biomarkers for osteoporosis – lessons learned: opportunities and challenges for diagnosis and monitoring of bone diseases” at Thursday at 8.10 am and Friday at 4.00 pm respectively.
Another focus at this year’s Osteologie 2020 is on the use of the NT-proBNP & FGF23 ELISAs, Klotho FIA and osteomiR kits in the osteology field.
More detailed, NT-proBNP is used for cardiovascular risk stratification in rheumatoid arthritis patients receiving NSAR therapy. FGF23 and Klotho play an important role in the regulation of phosphate and calcium homeostasis. osteomiR measures a panel of miRNAs to assess fracture risk.
Please come by- we’d love to see you there!
Periostin functions as a ligand for integrins to support adhesion and migration of tumor cells which leads to increased cell survival, invasion, angiogenesis and metastasis in different cancer types including breast cancer (BC).
In a recent study using the Biomedica Human Periostin ELISA, Periostin levels were significantly increased in women with primary, non-metastatic breast cancer over 60 as well as in postmenopausal women. No difference was observed in patients with and without the presence of disseminated tumor cells. However, high levels of circulating Periostin were associated with a poorer BC specific survival. These results warrant further studies on the role of Periostin in cancer patients.
More information on the Biomedica Periostin assays can be found here.
Hoffman et al. High circulating levels of Periostin are associated with a poor survival in primary, non-metastatic breast cancer patients. Am Ass Cancer Res 2019; 79(4 Suppl):Abstract nr P6-09-08
C4d has been regarded as an indirect footprint of an antibody-mediated response against an allograft. While C4d has emerged as a potential marker for antibody-mediated-rejection (AMR) after transplantation over the last decade, its use as a prognostic tool is still under debate.
A recent study has shown a positive association of C4d with cardiac allograft vasculopathy and death in heart transplant recipients. Late C4d positivity (> 1-year post-transplant) demonstrated an even higher risk for developing cardiac allograft vasculopathy and poor prognosis than early C4d positivity (within 1 year). The authors of the study suggest a prognostic role for C4d in heart transplantation warranting routine long-term detection of this marker in the pathologic evaluation of cardiac AMR.
Biomedica’s Anti C4d Antibodies allow the identification of human complement split product C4d in paraffin and frozen sections, and by flow cytometry.
Husain et al. Routine C4d immunohistochemistry in cardiac allografts: Long-term outcomes. J Heart Lung Transplant 2017: 36(12):1329-1335
Check out the Biomedica anti-C4d antibodies for ICH and FITC.
FGF23 (Fibroblast Growth Factor 23), a well-known marker for phosphate metabolism, has achieved independent significance in the cardiovascular system [1]. Several large-scale prospective studies have established FGF23 as an independent risk marker for heart failure and mortality [2,3]. There is also growing evidence that FGF-23 levels can predict the response to therapies aimed to reduce heart failure risk [4].
FGF23 is expressed in the heart and is significantly elevated in heart failure
Recent studies indicate that FGF23 is also expressed in the heart [5]. It is significantly enhanced in clinical and experimental settings of cardiac remodeling and heart failure independent of renal function [6, 10]. Secreted by cardiac myocytes, FGF23 can stimulate pro-fibrotic factors in myocytes to induce fibrosis-related pathways in fibroblasts and consequently cardiac fibrosis. While acting on cardiac myocytes, FGF23 directly induces pro-hypertrophic genes and promotes the progression of LVH (left ventricular hypertrophy) in an autocrine and paracrine fashion. Thus, enhanced FGF23 may promote cardiac injury in various clinical settings by endocrine and paracrine/autocrine mechanisms [7].
FGF23 measurement for prognosis and risk assessment in heart failure
Several large-scale prospective studies show a linear correlation between FGF23 levels and mortality risk, particularly because of LVH and systolic heart insufficiency (heart failure with reduced ejection fraction, HFREF) [2,8]. This clinically evident association between HFREF and FGF23, is likely explained by FGF23 ‘s direct cardiotoxic effects on cardiomyocytes.
Besides the known risk markers in HFREF patients such as serum sodium and BNP, the measurement of FGF23 can thus be of considerable use for risk stratification of individual patients. Of special relevance is the growing evidence that FGF23 levels can predict the response to a therapy with a blocker of the renin-angiotensin-aldosterone system [9].
Cardiovascular risk assessment under ACE therapy
In the PEACE Study (Prevention of Events With Angiotensin-Converting Enzyme) FGF23 was determined in 3,627 patients with stable ischemic heart disease (SIHD) [4]. Increased FGF23 levels correlated, with mortality rate and heart failure, but also identified those patients who benefitted significantly from treatment with ACE inhibitor. This effect was independent of renal function. These results indicate that FGF23 may become an attractive tool for individualized HFREF therapy. Patients with cardiorenal syndrome (combined heart and kidney failure) may benefit from FGF23 determination for estimation of individual risk and initiation of individualized treatment.
FGF23 and therapy monitoring
Patients with kidney disease show elevated serum concentrations of FGF23, associated with cardiovascular and all-cause mortality. A therapeutic approach to reduce increased FGF23 levels is the administration of (calcium-free) phosphatebinders (calcimimetics). The „EVOLVE“ study (2,985 patients receiving hemodialysis with secondary Hyperparathyroidism), demonstrated that treatment-induced reductions in serum FGF23 were associated with lower rates of cardiovascular death and major cardiovascular events. Among patients randomized to cinacalcet, a ≥30% reduction in serum FGF23 between baseline and week 20 was associated with a reduction in the relative hazard of the clinically relevant end point, cardiovascular mortality, sudden cardiac death, and heart failure [9].
Further studies on FGF23
Clearly more experimental and clinical studies are required to justify integrating routine measurement of FGF23 as risk marker for heart failure or to guide treatment. However, it is one of the few promising biomarkers that has high potential to ascertain the effect of FGF23 specific therapeutic interventions on clinically relevant endpoints [10].
Literature
[1] Hu MG, Shiizaki K, Kuro-o M, Moe OW. Fibroblast Growth Factor 23 and Klotho: Physiology and Pathophysiology of an Endocrine Network of Mineral Metabolism. Annu Rev Physiol. 2013;75:503-33.
[2] Brandenburg VM, Kleber ME, Vervloet MG, Tomaschitz A, Pilz S, Stojakovic T, Delgado G, Grammer TB, Marx N, März W, Scharnagl H. Fibroblast growth factor 23(FGF23) and mortality: the Ludwigshafen Risk and Cardiovascular Health Study. Atherosclerosis. 2014 Nov;237(1):53-9.
[3] Olauson H, Vervloet MG, Cozzolino M, Massy ZA, Ureña Torres P, Larsson TE. New insights into the FGF23-Klotho axis. Semin Nephrol. 2014 Nov;34(6):586-97.
[4] Udell JA, Morrow DA, Jarolim P, Sloan S, Hoffman EB, O’Donnell TF, Vora AN,Omland T, Solomon SD, Pfeffer MA, Braunwald E, Sabatine MS. Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. J Am Coll Cardiol. 2014 Jun 10;63(22):2421-8
[5] Itoh N, Ohta H, Nakayama Y, Konishi M. Roles of FGF signals in heart development, health, and disease. Front Cell Dev Biol (2016) 4:110. doi:10.3389/fcell.2016.00110.
[6] Andrukhova O, Slavic S, Odorfer KI, Erben RG. Experimental myocardial infarction upregulates circulating fibroblast growth factor-23. J Bone Miner Res (2015) 30:1831–9. doi:10.1002/jbmr.2527.
[7] Leifheit-Nestler M and Haffner D. Paracrine effects of FGF23 on the Heart. Frontiers in Endocrinology | www.frontiersin.org May 2018 | Volume 9 | Article 278.
[8] Almahmoud MF, Soliman EZ, Bertoni AG, Kestenbaum B, Katz R, Lima JAC, Ouyang P, Miller PE, Michos ED, Herrington DM; Fibroblast Growth Factor-23 and Heart Failure With Reduced Versus Preserved Ejection Fraction: MESA. J Am Heart Assoc. 2018 Sep 18;7(18):e008334.
[9] Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drüeke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J; For the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators. Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Circulation. 2015 July;132(1):27-39
[10] Vervloet M; Renal and Extrarenal Effects of Fibroblast Growth Factor 23. Nature Reviews. Nephrology 15, Nr. 2 (Februar 2019): 109–20.
Read more on our fully validated and CE marked FGF-23 (intact) ELISA and FGF-23 (C-terminal) multi-matrix ELISA for IVD use.
Features and Benefits
- RELIABLE and FULLY VALIDATED for plasma samples – according to ICH Q2
- FAST ONE-STEP ELISA – only 3.5 h total incubation time
- PLASMA-BASED STANDARDS and CONTROLS INCLUDED – for biologically reliable data
- CHARACTERIZED MONOCLONAL ANTIBODIES – high specificity and sensitivity guaranteed
- COMPARABLE RESULTS – correlates with existing methods
Sepsis-associated encephalopathy (SAE) has significant impact on the neurocognitive outcome of sepsis survivors. Biomarkers of brain injury and inflammation could help monitor encephalopathy in patients with sepsis.
Levels of NT-proCNP, a protein which is released during systemic inflammation, are highly elevated in both the plasma and CSF of sepsis patients with SAE. Since NT-proCNP levels in CSF and plasma NT-proCNP are highly correlated, plasma NT-proCNP might be a useful proxy biomarker to predict the emergence of SAE during the early phase of sepsis and detect neurological impairment at the later stages of the disease.
Plasma NT-proCNP measurement might be superior to S100B and NSE in SAE.
Ehler et al. Diagnostic value of NT-proCNP compared to NSE and S100B in cerebrospinal fluid and plasma of patients with sepsis-associated encephalopathy. Neurosci Lett. 2019;692:167-173.
For more information on the Biomedica NT-proCNP ELISA check out: https://www.bmgrp.com/product/cardiovascular/biomedica-nt-procnp-elisa/
Spinal cord injury (SCI) induces an acute alteration in bone metabolism. Although the aetiology of the bone disturbances is not precisely known, immobilisation reduces mechanical loading and the morphology of osteocytes, which are the primary mechanosensors. Periostin and Sclerostin are secreted mostly by osteocytes and are involved in bone’s mechanical response.
In a recent study using the Biomedica Periostin ELISA and Sclerostin ELISA, individuals with spinal cord injury presented higher serum Periostin levels in the acute phase and normal values in the chronic phase.
Conversely, serum Sclerostin levels were suppressed whatever the post-injury duration in the individuals with spinal cord injury. Paraplegia vs. tetraplegia and fragility fracture status seemed to influence Sclerostin levels only.
Maïmoun et al. Periostin and Sclerostin levels in individuals with spinal cord injury and their relationship with bone mass, bone turnover, fracture and osteoporosis status. Bone. 2019 127:612-619.
Vanin1 is a glycoprotein which is selectively expressed in renal tubular cells.
Urinary Vanin1 is a biomarker for the prediction of drug induced acute kidney injury. Compared with KIM-1 and NGAL, Vanin-1 has shown superior value in AKI detection. It can also help in the detection and monitoring of obstructive nephropathy.
Vanin-1 is a marker for the early detection of acute kidney injury
At Biomedica, we offer the FIRST fully validated VANIN-1 (urine) ELISA. Our quick, one-step ELISA is optimized for human urine samples and rigorously validated according to FDA/ICH/EMEA guidelines.
Check out the Vanin-1 ELISA validation data
Related literature:
Urinary Vanin-1 As a Novel Biomarker for Early Detection of Drug-Induced Acute Kidney Injury
Hosohata K et al., J Pharmoc Exp Therapeut, 2012
A Novel Biomarker for Acute Kidney Injury, Vanin-1, for Obstructive Nephropathy: A Prospective Cohort Pilot Study
Washino S. et al., Int J Mol Sci, 2019
Abstract
Background: Vanin-1 is a novel acute kidney injury (AKI) biomarker that has not been clinically investigated as a biomarker for obstructive nephropathy. This study investigated the diagnostic value of vanin-1 as a biomarker for adult obstructive nephropathy by comparing it to existing AKI biomarkers. Methods: A total of 49 patients, 21 controls, and 28 hydronephrosis (HN) cases were assessed. AKI biomarkers in bladder (BL) urine and renal pelvic (RP) urine in the HN group were compared to each BL marker in the control group. In a subgroup of cases receiving interventions for obstructive nephropathy, the BL values of each biomarker were assessed after the intervention. Results: RP vanin-1 levels were significantly higher while BL vanin-1 levels were marginally higher in the HN group than in the control group. The area under the receiver operating characteristics curve values for RP and BL vanin-1 were 0.9778 and 0.6386, respectively. In multivariate analyses, BL vanin-1 and N-acetyl-β-D-glucosaminidase (NAG), but not kidney injury molecule-1 (KIM-1) or neutrophil gelatinase-associated lipocalin (NGAL), were independent factors for predicting the presence of HN. In cases receiving interventions, vanin-1 decreased significantly from 1 week after the intervention in cases of moderate to severe obstructive nephropathy compared to RP values at baseline. Conclusion: Urinary vanin-1 is a useful biomarker to detect and monitor the clinical course of obstructive nephropathy.
Meet us during ASN Kidney Week taking place from November 5-10 2019 in Washington, DC at booth no. 2005 Hosted by the American Society of Nephrology it’s the world’s premier nephrology meeting with more than 13,000 kidney specialists from across the globe. It provides participants with exciting and challenging opportunities to exchange knowledge, learn about the latest scientific and medical advances and listen to engaging and provocative discussions with leading experts in the field. To improve the outcomes of patients with kidney disease, risk stratification and disease detection in an early stage is important. Meet Gabriela Berg to learn more about Biomedica’s high-quality innovative biomarker ELISAs for clinical research. kidneyweek